Retatrutide 10mg

Retatrutide is a next‑generation investigational peptide designed to target multiple metabolic pathways simultaneously. As a triple‑agonist (GLP‑1, GIP, and glucagon receptor activity), it is regarded as an advanced research compound for studying weight regulation, energy expenditure, and glucose homeostasis in preclinical environments.

• Product Name: Retatrutide10mg
• Catalogue Number: RETA-010
• Molecular Formula: C187H284N50O59
• CAS Number: 2383116-03-5
• Molecular Weight: 4211.56 g/mol
• Purity: ≥98%
• Compound Type: Peptide / Triple‑Agonist Research Compound
• Form: Lyophilised Solid – What is this? Read more here.

Why Is Retatrutide of Interest to the Research Community?

Retatrutide has attracted significant attention in metabolic and endocrine research due to its unique triple‑agonist receptor profile. By simultaneously engaging GLP‑1, GIP, and glucagon receptors, Retatrutide is being explored for its effects on energy expenditure, adipose metabolism, glycaemic regulation, and appetite signalling. Early scientific investigations indicate its potential value in studying obesity, insulin sensitivity, hepatic lipid processing, and thermogenic mechanisms. This makes Retatrutidea compelling tool for understanding complex metabolic interactions.

Usage and Storage:

Retatrutide is supplied as a lyophilised powder to maintain integrity and long‑term stability. For best results, follow our reconstitution and storage guidelines. Learn more about peptide storage

Synthesis and Quality Assurance:

Each batch of Retatrutide is synthesised using solid‑phase peptide construction followed by high‑precision purification steps such as HPLC. Material is tested for identity, purity, and structural conformity using validated analytical techniques. Our manufacturing partners adhere to strict quality assurance protocols to ensure batch‑to‑batch reliability that supports robust scientific outcomes.

Why Choose Simply Peptides for Retatrutide in the UK?

Simply Peptides provides premium‑grade research compounds backed by transparent sourcing and rigorous quality control. Our direct partnership with manufacturing facilities ensures complete oversight of production workflows, enabling us to deliver consistent, high‑purity peptides trusted by researchers across the UK and internationally.

External Resources for Researchers

• PubMed — Retatrutide (search)
• Google Scholar — Retatrutide literature

Alternative Names for Retatrutide

Retatrutide may appear in research literature under several identifiers:

• LY3437943 – Development code name
• Triple Agonist Peptide (GLP‑1/GIP/Glucagon)
• Retatrutide – Commonly used alternative spelling

These names may vary depending on supplier, publication, or region. Always confirm identity and purity when sourcing compounds for research.

Legal and Safety Information:

Simply Peptides supplies Retatrutide exclusively for scientific research. All compounds must be handled by qualified professionals familiar with laboratory safety and peptide handling protocols. These materials are not intended to diagnose, treat, or prevent any disease.

If you require high‑quality Retatrutide for research in the UK, explore our full catalogue of advanced peptides designed to support scientific innovation.

COA & Testing Reports

Certificate of Analysis (COA) & Independent Testing

Every batch of Retatrutide is supplied with a Certificate of Analysis (COA) detailing purity, identity, appearance, and analytical verification. This ensures transparency and provides essential documentation for research compliance.

Independent third‑party laboratories also perform additional analyses, including identity confirmation and impurity screening. Full reports are available to qualified researchers upon request.

• Batch‑specific COA are available here
• Third‑party testing results available here
• Analytical methods include HPLC, Mass Spectrometry, and Microbial Screening. Access documentation here

Note: All documentation is provided for research reference only and is not intended to support clinical or therapeutic claims.